Skip to main content

Table 2 Outcomes from randomization to end of study visit 95% CI: 95% confidence interval; IQR: interquartile range; MVS: mechanical ventilatory support; SD: standard deviation; # total number of events, * All adverse events were non-serious

From: Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

Outcome Ivermectin (N = 250) Placebo (N = 251) Odds Ratio (95% CI) p value
Primary
 Hospitalization, N (%) 14 (5.60) 21 (8.37) 0.65 (0.32–1.31) 0.227
Secondary
 Time to hospitalization days (in those who were hospitalized), median (IQR) 3.5 (3–5) 3 (2–5) 0.59
 Invasive MVS, N (%) 4 (1.60) 3 (1.20) 1.34 (0.30–6.07) 0.70
 Time to invasive MVS days (in those who required MVS), mean (±SD) 5.25 (1.71) 10 (2) 0.019
 Negative nasal swab day 3, N (%) 113 (47.08) 120 (49.79) 0.90 (0.63–1.28) 0.55
 Negative nasal swab day 12, N (%) 212 (89.08) 221 (92.47) 0.76 (0.45–1.27) 0.29
 Dialysis, N (%) 1 (0.40) 1 (0.40) 1.00 (0.06–16.14) 1
 All-cause mortality, N (%) 4 (1.60) 3 (1.20) 1.34 (0.30–6.07) 0.70
 Safety (adverse events)#, total (%) * 45 (18.00) 53 (21.11) 0.6